Krystal Biotech

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell KRYS and other ETFs, options, and stocks.

About KRYS

Krystal Biotech, Inc. operates as a biotechnology company, which engages in developing and commercializing pharmaceutical products. It offers the product, VYJUVEK. 

CEO
Krish S. Krishnan
CEOKrish S. Krishnan
Employees
275
Employees275
Headquarters
Pittsburgh, Pennsylvania
HeadquartersPittsburgh, Pennsylvania
Founded
2016
Founded2016
Employees
275
Employees275

KRYS Key Statistics

Market cap
7.58B
Market cap7.58B
Price-Earnings ratio
39.21
Price-Earnings ratio39.21
Dividend yield
Dividend yield
Average volume
271.45K
Average volume271.45K
High today
$267.48
High today$267.48
Low today
$252.92
Low today$252.92
Open price
$254.51
Open price$254.51
Volume
349.33K
Volume349.33K
52 Week high
$267.48
52 Week high$267.48
52 Week low
$122.80
52 Week low$122.80

Stock Snapshot

As of today, Krystal Biotech(KRYS) shares are valued at $261.41. The company's market cap stands at 7.58B, with a P/E ratio of 39.21.

On 2026-01-11, Krystal Biotech(KRYS) stock moved within a range of $252.92 to $267.48. With shares now at $261.41, the stock is trading +3.4% above its intraday low and -2.3% below the session's peak.

Trading volume for Krystal Biotech(KRYS) stock has reached 349.33K, versus its average volume of 271.45K.

The stock's 52-week range extends from a low of $122.80 to a high of $267.48.

The stock's 52-week range extends from a low of $122.80 to a high of $267.48.

KRYS News

Simply Wall St 1d
Krystal Biotech Is Up 5.9% After Positive KB407 CF Gene Therapy Update and CORAL-3 Plans

In early January 2026, Krystal Biotech reported a positive interim update from the highest-dose cohort of its Phase 1 CORAL-1 study of inhaled gene therapy KB40...

Krystal Biotech Is Up 5.9% After Positive KB407 CF Gene Therapy Update and CORAL-3 Plans
TipRanks 2d
Krystal Biotech advances KB407 with positive CF trial data

Claim 70% Off TipRanks Premium Krystal Biotech ( (KRYS) ) just unveiled an update. On January 8, 2026, Krystal Biotech reported positive interim results from...

TipRanks 2d
Krystal Biotech announces interim update from highest dose cohort of CORAL-1

Krystal Biotech (KRYS) announced an interim clinical update from the highest dose cohort of CORAL-1, the company’s multi-center, dose escalation Phase 1 study e...

Analyst ratings

100%

of 12 ratings
Buy
100%
Hold
0%
Sell
0%

More KRYS News

TipRanks 5d
Krystal Biotech upgraded to Buy from Neutral at Citi

Citi upgraded Krystal Biotech (KRYS) to Buy from Neutral with a price target of $309, up from $198. The firm sees opportunities in SMID-cap biotech heading into...

People also own

Based on the portfolios of people who own KRYS. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.